Biomarker Testing in Non-Small Cell Lung Cancer in Routine Care: Analysis of the First 3,717 Patients in the German Prospective, Observational, Nation-Wide CRISP Registry (AIO-TRK-0315)

An increasing number of treatment-determining biomarkers has been identified in non–small cell lung cancer (NSCLC), and molecular testing is recommended to enable optimal individualized treatment. However, data on implementation of these recommendations in the “real-world” setting are scarce. This study presents comprehensive details on the frequency, methodology, and results of biomarker testing of advanced NSCLC in Germany.